Abstract Number: 1613 • 2016 ACR/ARHP Annual Meeting
Safe and Effective Tocilizumab Therapy in Elderly Patients with Rheumatoid Arthritis
Background/Purpose: The non-interventional study ICHIBAN was set up in 2010 to evaluate the effectiveness and safety of intravenously administered Tocilizumab (TCZ IV) in patients (pts)…Abstract Number: 2519 • 2016 ACR/ARHP Annual Meeting
Predictors of Flare in Rheumatoid Arthritis Patients Treated Preventively with Rituximab: A Prospective Study Using Ultrasound and Patient Reported Outcomes
Title: Predictors of flare in rheumatoid arthritis patients treated preventively with rituximab: a prospective study using ultrasound and patient reported outcomes Background/Purpose: Rituximab (RTX) is…Abstract Number: 101 • 2016 ACR/ARHP Annual Meeting
Rheumatology Care Utilization and Geographic Distance from Rheumatology Sites within the United States Veteran Affairs Health Care System
Background/Purpose: Within the Veteran Affairs (VA) health care system, there are often large geographic distances between patients and rheumatology providers. The purpose of this study…Abstract Number: 633 • 2016 ACR/ARHP Annual Meeting
High Similarity Between Ex-Vivo Inhibited Cytokine Profiling By Golimumab and Adalimumab As a Putative Explanation for Inferior Treatment Response to Golimumab after Adalimumab Failure in Rheumatoid Arthritis
Background/Purpose: Better prediction of treatment response to biologics in rheumatoid arthritis (RA) would contribute to optimal individualized treatment. Clinical data suggest that the response of…Abstract Number: 1617 • 2016 ACR/ARHP Annual Meeting
Treatment with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, Improves Fatigue and Health-Related Physical and Emotional Well Being in Patients with Active Rheumatoid Arthritis Refractory to Conventional or Biologic Therapy: Results of 2 Global, Placebo-Controlled, Phase 3 Trials
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) often experience both substantial fatigue and a decline in their health-related physical and emotional well-being. Sirukumab is a…Abstract Number: 2521 • 2016 ACR/ARHP Annual Meeting
Lower Baseline 14-3-3η Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients
Background/Purpose: Serum 14-3-3η is a mechanistic marker that is involved in the pathogenesis of RA and is a potent up-regulator of IL-6. We previously reported…Abstract Number: 119 • 2016 ACR/ARHP Annual Meeting
Impact of Socioeconomic Status on Disease Outcomes in Japanese Patients with Rheumatoid Arthritis Under the Japanese National Insurance System
Background/Purpose: Several studies showed lower socioeconomic status (SES) was associated with higher disease activity and lower quality of life (QOL) in patients with rheumatoid arthritis…Abstract Number: 954 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Different Dosages of Retreatment of Rituximab in Combination with Leflunomide: Results from a Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study
Background/Purpose: Use of biologicals such as Rituximab (RTX) in Rheumatoid Arthritis (RA) is effective and often only licensed in combination with Methotrexate (MTX). In cases…Abstract Number: 1631 • 2016 ACR/ARHP Annual Meeting
Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. In the phase 3 MOBILITY (NCT01061736) and TARGET (NCT01709578) studies, sarilumab (150 or 200 mg subcutaneously…Abstract Number: 2548 • 2016 ACR/ARHP Annual Meeting
Single 1g Infusion Vs Double 1g Infusion of Rituximab in Rheumatoid Arthritis in a Large Teaching Hospital: Potential Clinical Benefits and Financial Savings
Background/Purpose: Recent trial data from Mariette et al. investigating a single-dose 1g rituximab regimen as opposed to a double-dose 1g rituximab regimen in patients with…Abstract Number: 129 • 2016 ACR/ARHP Annual Meeting
Ultrasound Is More Reliable Than Inflammatory Parameters (ESR and CRP) to Evaluate Disease Activity in Rheumatoid Arthritis Patients on Tocilizumab Therapy
Background/Purpose: The goal of therapy of rheumatoid arthritis(RA) is to achieve a remission or at least low disease activity. Tocilizumab completely interrupt the effect of…Abstract Number: 1036 • 2016 ACR/ARHP Annual Meeting
Dominant B-Cell Receptor Clones in Peripheral Blood Predict Onset of Arthritis in Individuals at Risk for Rheumatoid Arthritis
Background/Purpose: The onset of seropositive rheumatoid arthritis (RA) is preceded by the presence of specific autoantibodies in the absence of synovial inflammation. Only a subset…Abstract Number: 1647 • 2016 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 8 Years
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The objective of this analysis was to report tofacitinib safety and tolerability…Abstract Number: 2571 • 2016 ACR/ARHP Annual Meeting
Distinct Oral and Fecal Community Profiles Enriched in Opportunistic Pathogens in RA Patients and First Degree Relatives Are Influenced By Environmental Risk Factors, Including Smoking, Dental History and Lung Infection
Background/Purpose: In the Rheumatoid Arthritis (RA) prodrome, genetic predisposition intersects with environmental risk factors, such as smoking, periodontal disease and respiratory infection, however no studies…Abstract Number: 134 • 2016 ACR/ARHP Annual Meeting
Synovitis Assessed By the German 7-Joint Ultrasound Score (US7S) Is Associated with the Reversible Activity-Related Component of Physical Disability in Patients with Rheumatoid Arthritis
Background/Purpose: Restoring normal functioning is a major therapeutic aim. Differences in the sources of functional limitations should be considered in the interpretation of functional measures.…
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 56
- Next Page »